drachma
if you're talking about a hostile takeover, IMO that's not on the cards as management have massive holdings to resist such a move. I forget the figures but check out the MSB website and it's there.
Ilescu has a few clues about the vulnerability of australian biotechs in the past and has taken preventive measures.
Further, the 'deal of the year' 2010 between Cepahlon/now Teva and MSB was not awarded for no reason. Ilescu has a few clues.
IMO.
DV
setting the record straight, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
-0.065(6.10%) |
Mkt cap ! $1.141B | |||
| Open | High | Low | Value | Volume |
| $1.04 | $1.04 | 99.5¢ | $3.281M | 3.243M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 23962 | $1.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 33833 | 12 |
View Market Depth
| Last trade - 15.23pm 04/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |